Polypharmacy and Off-label Drug Use in Dentistry: knowledge, attitudes and practices of California dental hygienists

References

1. ↵
   1. Köberlein J,
   2. Gottschall M,
   3. Czarnecki K,
   4. et al

   . General practitioners' views on polypharmacy and its consequences for patient health care. BMC Fam Pract. 2013 Aug 15;14:119-25.

   OpenUrlPubMed
2. ↵
   1. Jenny JL,
   2. Jenny C,
   3. Jayadevan S,
   4. et al

   . Nurses opinion on the attributes of polypharmacy in patient safety. Acta Medica Iranica. 2012 Jul 1;50(7):516-21.

   OpenUrlPubMed
3. ↵
   1. Kantor ED,
   2. Rehm CD,
   3. Haas JS,
   4. et al

   . Trends in prescription drug use among adults in the United States from 1999-2012. JAMA. 2015 Nov 3; 314(17):1818-30.

   OpenUrlCrossRefPubMed
4. ↵
   1. U.S. Food and Drug Administration

   . Guidance for industry: responding to unsolicited requests for off-label information about prescription drugs and medical devices. [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2011 Dec [cited 2016 Mar 26]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm285145.pdf.
5. ↵
   1. Eguale T,
   2. Buckeridge DL,
   3. Verma A,
   4. et al

   . Association of off-label drug use and adverse drug events in an adult population. JAMA Intern Med. 2015 Nov 2;1-9.
6. ↵
   1. Gupta SK,
   2. Nayak RP

   . Off-label use of medicine: Perspective of physicians, patients, pharmaceutical companies and regulatory authorities. J Pharmacol Pharmacother. 2014 Nov 20;5(2):88-92.

   OpenUrl
7. ↵
   1. Hopkins PN,
   2. Polukoff GI

   . Risk of valvular heart disease associated with use of fenfluramine. BMC Cardiovasc Disord. 2003 Jun 11;3(5):1-13.

   OpenUrlCrossRefPubMed
8. ↵
   1. Wadden TA,
   2. Berkowitz RI,
   3. Silvestry F,
   4. et al

   . The fenphen finale: A study of weight loss and valvular heart disease. Obes Res. 1998 Jul 1;6(4):278-84.

   OpenUrlPubMedWeb of Science
9. ↵
   1. Centers for Disease Control and Prevention

   . Dietary supplement use among U.S. adults has increased since NHANES III (1988–1994). [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; 2011 Apr [cited 2016 Mar 26]. Available from: http://www.cdc.gov/nchs/data/databriefs/db61.htm.
10. ↵
    1. National Institute of Health and Human Services

    . Frequently asked questions [Internet]. Bethesda (MD): National Institute of Health and Human Services: Office of Dietary Supplements; 2013 Jul [cited 2017 Sept 9]. Available from: https://ods.od.nih.gov/Health_Information/ODS_Frequently_Asked_Questions.aspx
11. ↵
    1. Lin CS

    . (Department of Health and Human Services, Rockville, MD) [Internet]. Letter to: Terry L. Joritz (GC America, Incorporated, Alsip, ILL). 2004 Oct 20. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf4/k042200.pdf
12. ↵
    1. U.S. Food and Drug Administration

    . Inspections, compliance, enforcement, and criminal investigations [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2012 Nov [cited 2016 Apr 8]. Available from https://www.fda.gov/ICECI/EnforcementActions/default.htm
13. ↵
    1. American Dental Association Center for Evidence Based Dentistry

    . Topical fluoride for caries prevention: full report of the updated clinical recommendations and supporting systematic review. [Internet]. Chicago: American Dental Association; 2013 Nov. [cited 2017 Aug 22]. Available from: http://ebd.ada.org/~/media/EBD/Files/Topical_fluoride_for_caries_prevention_2013_update.pdf?la=en
14. ↵
    1. U.S. Food and Drug Administration

    . Premarket notification: Dentsply international. U.S. [Internet]. Silver Spring (MD): Food and Drug Administration; 2012 Oct [cited 2017 Apr 8]. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf12/k122331.pdf
15. ↵
    1. Hawkins R,
    2. Noble J,
    3. Locker D,
    4. et al

    . A comparison of the costs and patient acceptability of professionally applied topical fluoride foam and varnish. J Public Health Dent. 2004 Jun 1;64(2):106-10.

    OpenUrlCrossRefPubMed
16. ↵
    1. Lexicomp.

    Chlorohexidine gluconate (Lexi-drugs). [Internet]. Lexicomp: Indianapolis, IN: Lexicomp; 2017 Mar [cited 2017 Apr 8]. Available from: http://www.wolterskluwercdi.com/
17. ↵
    1. Li Y,
    2. Tanner A

    . Effect of antimicrobial intervention on oral microbiota associated with early childhood caries. Pediatr Dent. 2015 May 1;37(3):226.

    OpenUrl
18. ↵
    1. Rethman MP,
    2. Beltrán-Aguilar ED,
    3. Billings RJ,
    4. et al

    . Non-fluoride caries preventive agents: full report of a systematic review and evidence-based recommendations. American Dental Association Center for Evidence Based Dentistry [Internet] 2011 May. [cited 2017 Aug 22]. Available from http://ebd.ada.org/~/media/EBD/Files/clinical_recommendations_non_fluoride_caries_preventive_agents_full_report.pdf?la=en
19. ↵
    1. Perayil J,
    2. Menon K S,
    3. Fenol A,
    4. et al

    . Comparison of the efficacy of subgingival irrigation with 2% povidoneiodine and tetracycline HCl in subjects with chronic moderate periodontitis: A clinical microbiological study. Dent Res J. 2016 Mar;13(2):98-109.

    OpenUrl
20. ↵
    1. Miziara I,
    2. Chagury A,
    3. Vargas C,
    4. et al

    . Therapeutic options in idiopathic burning mouth syndrome: literature review. Int Arch Otorhinolaryngol. 2015 Jan;19(1):86-9.

    OpenUrl
21. ↵
    1. Clauson KA,
    2. Marsh WA,
    3. Polen HH,
    4. Seamon MJ

    . Clinical decision support tools: Analysis of online drug information databases. BMC Med Inform Decis Mak. 2007 Mar 8;7(7):1-7.

    OpenUrlCrossRefPubMed
22. ↵
    1. Radley DC,
    2. Finkelstein SN,
    3. Stafford RS

    . Off-label prescribing among office-based physicians. Arch Intern Med. 2006 May 8;166(9):1021-26.

    OpenUrlCrossRefPubMedWeb of Science
23. ↵
    1. Ghinea N,
    2. Lipworth W,
    3. Kerridge I

    . Evidence, regulation and ‘rational’ prescribing: the case of gabapentin for neuropathic pain. J Eval Clin Pract. 2014 May;21(1):28-33.

    OpenUrl
24. ↵
    1. Wittich CM,
    2. Burkle CM,
    3. Lanier WL

    . Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc. 2012 Oct;87(10):982–90.

    OpenUrlCrossRefPubMed
25. ↵
    1. Kimland E,
    2. Odlind V

    . Off-label drug use in pediatric patients. Pharmacol Ther. 2012 Apr 4;91(5):796–801.

    OpenUrl
26. ↵
    1. Hurlbutt M,
    2. Bray K,
    3. Mitchell TV,
    4. Stephens J

    . California dental hygienists' knowledge, attitudes and practices regarding herbal and dietary supplements. J Dent Hyg. 2011 Sept 1;85(4):285-96.

    OpenUrlFREE Full Text
27. ↵
    1. Commission on Dental Accreditation

    . Accreditation standards for dental hygiene education programs [Internet]. Chicago: American Dental Association; 2013 [cited 2017 Jan 8]. Available from http://www.ada.org/~/media/CODA/Files/dh.pdf?la=en
28. ↵
    1. American Dental Education Association

    . Compendium of curriculum guidelines (revised edition): Allied dental education programs [Internet]. Washington DC: American Dental Education Association; 2015-2016 May [cited 2017 Jan 8]. Available from http://www.adea.org/BDEBlog.aspx?id=27917&blogid=27619
29. ↵
    1. Haveles EB

    . Applied pharmacology for the dental hygienist. 7th rev. ed. St. Louis: Mosby, Elsevier Inc. 2016. 368 p.
30. ↵
    1. Keijsers CJ,
    2. Brouwers JR,
    3. de Wildt DJ,
    4. et al

    . A comparison of medical and pharmacy students' knowledge and skills of pharmacology and pharmacotherapy. Br J Clin Pharmacol. 2014 Oct 1;78(4):781-88.

    OpenUrl
31. ↵
    1. College of Registered Dental Hygienists of Alberta

    . HPA frequently asked questions. [Internet]. Edmonton: College of Registered Dental Hygienists of Alberta; 2013 [cited 2016 Dec 23]; [about 2 screens]. Available from http://www.crdha.ca/legislation/hpa-frequently-asked-questions.aspx
32. ↵
    1. College of Registered Dental Hygienists of Alberta

    . Learn more about CRDHA dental hygienist prescribing education [Internet]. Edmonton: College of Registered Dental Hygienists of Alberta; 2015 Dec [cited 2016 Dec 23]. Available from http://www.crdha.ca/media/104984/dh_brochureall_online_feb-2015_final.pdf.
33. ↵
    1. College of Registered Dental Hygienists of Alberta

    . Restricted activities authorization table. [Internet]. Edmonton:2015 Dec [cited 2016 Dec 23]. Available from http://www.crdha.ca/media/223266/restricted-activities-authorization-table-updated-dec-2015.pdf
34. ↵
    1. College of Registered Dental Hygienists of Alberta

    . Guidelines regarding prescription and non-prescription drugs in dental hygiene practice [Internet]. Edmonton: College of Registered Dental Hygienists of Alberta; 2008 Jun [cited 2016 Dec 23]. Available from http://www.crdha.ca/media/1487/crdha-drug-guidelines.pdf
35. ↵
    1. Chen DT,
    2. Wynia MK,
    3. Moloney RM,
    4. Alexander GC

    . U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey. Pharmacoepidemiol Drug Saf. 2009 Jul 8;18(11):1094-1100.

    OpenUrlCrossRefPubMedWeb of Science
36. ↵
    1. American Dental Association

    . Clinical recommendations for use of professionally-applied or prescription-strength, home-use topical fluoride agents for caries prevention in patients at elevated risk of developing caries. [Internet]. Chicago: American Dental Association; 2013 [cited 2016 Dec 23]. Available from http://ebd.ada.org/en/~/media/EBD/Files/ADA_Evidence-based_Topical_Fluoride_Chairside_Guide